| Aker Kasten Eye Center | |
|
Aker Kasten Eye Center 1445 Nw Boca Raton Blvd Boca Raton FL 33432 | |
| (561) 338-7722 | |
| (561) 886-1033 |
| Full Name | Aker Kasten Eye Center |
|---|---|
| Speciality | General Practice |
| Location | Aker Kasten Eye Center, Boca Raton, Florida |
| Authorized Official Name and Position | Kim Harrington (ADMINISTRATOR) |
| Authorized Official Contact | 5613387722 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Aker Kasten Eye Center Aker Kasten Eye Center 1445 Nw Boca Raton Blvd Boca Raton FL 33432 Ph: (561) 338-7722 | Aker Kasten Eye Center Aker Kasten Eye Center 1445 Nw Boca Raton Blvd Boca Raton FL 33432 Ph: (561) 338-7722 |
| NPI Number | 1053475590 |
|---|---|
| Provider Enumeration Date | 12/20/2006 |
| Last Update Date | 02/12/2009 |
| Medicare PECOS PAC ID | 9234038902 |
|---|---|
| Medicare Enrollment ID | O20060501000470 |
News Archive
Hospitals can dramatically reduce the number of life-threatening central line infections in pediatric cancer patients by following a set of basic precautions, by encouraging families to speak up when they observe noncompliance with the protocol and by honest analysis of the root cause behind every single infection, according to a new Johns Hopkins Children's Center study.
A new report published today, by the South Asian Health Foundation (SAHF) highlights that misunderstanding of diabetes in the South Asian community can be addressed by culturally appropriate education programmes.
With each new amyloid-targeting treatment for Alzheimer's disease that has been developed, there has been a corresponding concern. For example, antibodies targeting amyloid-β peptide (Aβ) produce inflammation in the brain in some patients.
An active lifestyle helps preserve gray matter in the brains of older adults and could reduce the burden of dementia and Alzheimer's disease (AD), according to a study presented today at the annual meeting of the Radiological Society of North America (RSNA).
Ascenta Therapeutics announced today that following the approval by the U.S. Food and Drug Administration (FDA) of its Investigational New Drug (IND) Application for AT-406, an orally-active, small molecule, multi-IAP antagonist, the company will initiate a Phase I clinical trial in patients with advanced cancer during the fourth quarter of 2009.
› Verified 3 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053475590 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208D00000X | General Practice | (* (Not Available)) | Primary |
| Provider Name | Jill F Rodila |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1568487676 PECOS PAC ID: 4688561145 Enrollment ID: I20040301000805 |
News Archive
Hospitals can dramatically reduce the number of life-threatening central line infections in pediatric cancer patients by following a set of basic precautions, by encouraging families to speak up when they observe noncompliance with the protocol and by honest analysis of the root cause behind every single infection, according to a new Johns Hopkins Children's Center study.
A new report published today, by the South Asian Health Foundation (SAHF) highlights that misunderstanding of diabetes in the South Asian community can be addressed by culturally appropriate education programmes.
With each new amyloid-targeting treatment for Alzheimer's disease that has been developed, there has been a corresponding concern. For example, antibodies targeting amyloid-β peptide (Aβ) produce inflammation in the brain in some patients.
An active lifestyle helps preserve gray matter in the brains of older adults and could reduce the burden of dementia and Alzheimer's disease (AD), according to a study presented today at the annual meeting of the Radiological Society of North America (RSNA).
Ascenta Therapeutics announced today that following the approval by the U.S. Food and Drug Administration (FDA) of its Investigational New Drug (IND) Application for AT-406, an orally-active, small molecule, multi-IAP antagonist, the company will initiate a Phase I clinical trial in patients with advanced cancer during the fourth quarter of 2009.
› Verified 3 days ago
| Provider Name | Kelli F Wolper |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1639130115 PECOS PAC ID: 8426069303 Enrollment ID: I20060505000858 |
News Archive
Hospitals can dramatically reduce the number of life-threatening central line infections in pediatric cancer patients by following a set of basic precautions, by encouraging families to speak up when they observe noncompliance with the protocol and by honest analysis of the root cause behind every single infection, according to a new Johns Hopkins Children's Center study.
A new report published today, by the South Asian Health Foundation (SAHF) highlights that misunderstanding of diabetes in the South Asian community can be addressed by culturally appropriate education programmes.
With each new amyloid-targeting treatment for Alzheimer's disease that has been developed, there has been a corresponding concern. For example, antibodies targeting amyloid-β peptide (Aβ) produce inflammation in the brain in some patients.
An active lifestyle helps preserve gray matter in the brains of older adults and could reduce the burden of dementia and Alzheimer's disease (AD), according to a study presented today at the annual meeting of the Radiological Society of North America (RSNA).
Ascenta Therapeutics announced today that following the approval by the U.S. Food and Drug Administration (FDA) of its Investigational New Drug (IND) Application for AT-406, an orally-active, small molecule, multi-IAP antagonist, the company will initiate a Phase I clinical trial in patients with advanced cancer during the fourth quarter of 2009.
› Verified 3 days ago
| Provider Name | Meir M Baalhaness |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1114001427 PECOS PAC ID: 1052344462 Enrollment ID: I20071119000186 |
News Archive
Hospitals can dramatically reduce the number of life-threatening central line infections in pediatric cancer patients by following a set of basic precautions, by encouraging families to speak up when they observe noncompliance with the protocol and by honest analysis of the root cause behind every single infection, according to a new Johns Hopkins Children's Center study.
A new report published today, by the South Asian Health Foundation (SAHF) highlights that misunderstanding of diabetes in the South Asian community can be addressed by culturally appropriate education programmes.
With each new amyloid-targeting treatment for Alzheimer's disease that has been developed, there has been a corresponding concern. For example, antibodies targeting amyloid-β peptide (Aβ) produce inflammation in the brain in some patients.
An active lifestyle helps preserve gray matter in the brains of older adults and could reduce the burden of dementia and Alzheimer's disease (AD), according to a study presented today at the annual meeting of the Radiological Society of North America (RSNA).
Ascenta Therapeutics announced today that following the approval by the U.S. Food and Drug Administration (FDA) of its Investigational New Drug (IND) Application for AT-406, an orally-active, small molecule, multi-IAP antagonist, the company will initiate a Phase I clinical trial in patients with advanced cancer during the fourth quarter of 2009.
› Verified 3 days ago
| Provider Name | Anup A Kubal |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1003952466 PECOS PAC ID: 4284771361 Enrollment ID: I20091021000723 |
News Archive
Hospitals can dramatically reduce the number of life-threatening central line infections in pediatric cancer patients by following a set of basic precautions, by encouraging families to speak up when they observe noncompliance with the protocol and by honest analysis of the root cause behind every single infection, according to a new Johns Hopkins Children's Center study.
A new report published today, by the South Asian Health Foundation (SAHF) highlights that misunderstanding of diabetes in the South Asian community can be addressed by culturally appropriate education programmes.
With each new amyloid-targeting treatment for Alzheimer's disease that has been developed, there has been a corresponding concern. For example, antibodies targeting amyloid-β peptide (Aβ) produce inflammation in the brain in some patients.
An active lifestyle helps preserve gray matter in the brains of older adults and could reduce the burden of dementia and Alzheimer's disease (AD), according to a study presented today at the annual meeting of the Radiological Society of North America (RSNA).
Ascenta Therapeutics announced today that following the approval by the U.S. Food and Drug Administration (FDA) of its Investigational New Drug (IND) Application for AT-406, an orally-active, small molecule, multi-IAP antagonist, the company will initiate a Phase I clinical trial in patients with advanced cancer during the fourth quarter of 2009.
› Verified 3 days ago
| Provider Name | Shailesh K Gupta |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1467424382 PECOS PAC ID: 6901943695 Enrollment ID: I20091029000237 |
News Archive
Hospitals can dramatically reduce the number of life-threatening central line infections in pediatric cancer patients by following a set of basic precautions, by encouraging families to speak up when they observe noncompliance with the protocol and by honest analysis of the root cause behind every single infection, according to a new Johns Hopkins Children's Center study.
A new report published today, by the South Asian Health Foundation (SAHF) highlights that misunderstanding of diabetes in the South Asian community can be addressed by culturally appropriate education programmes.
With each new amyloid-targeting treatment for Alzheimer's disease that has been developed, there has been a corresponding concern. For example, antibodies targeting amyloid-β peptide (Aβ) produce inflammation in the brain in some patients.
An active lifestyle helps preserve gray matter in the brains of older adults and could reduce the burden of dementia and Alzheimer's disease (AD), according to a study presented today at the annual meeting of the Radiological Society of North America (RSNA).
Ascenta Therapeutics announced today that following the approval by the U.S. Food and Drug Administration (FDA) of its Investigational New Drug (IND) Application for AT-406, an orally-active, small molecule, multi-IAP antagonist, the company will initiate a Phase I clinical trial in patients with advanced cancer during the fourth quarter of 2009.
› Verified 3 days ago
| Provider Name | Ann G Kasten |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1265401079 PECOS PAC ID: 4880728815 Enrollment ID: I20100812001010 |
News Archive
Hospitals can dramatically reduce the number of life-threatening central line infections in pediatric cancer patients by following a set of basic precautions, by encouraging families to speak up when they observe noncompliance with the protocol and by honest analysis of the root cause behind every single infection, according to a new Johns Hopkins Children's Center study.
A new report published today, by the South Asian Health Foundation (SAHF) highlights that misunderstanding of diabetes in the South Asian community can be addressed by culturally appropriate education programmes.
With each new amyloid-targeting treatment for Alzheimer's disease that has been developed, there has been a corresponding concern. For example, antibodies targeting amyloid-β peptide (Aβ) produce inflammation in the brain in some patients.
An active lifestyle helps preserve gray matter in the brains of older adults and could reduce the burden of dementia and Alzheimer's disease (AD), according to a study presented today at the annual meeting of the Radiological Society of North America (RSNA).
Ascenta Therapeutics announced today that following the approval by the U.S. Food and Drug Administration (FDA) of its Investigational New Drug (IND) Application for AT-406, an orally-active, small molecule, multi-IAP antagonist, the company will initiate a Phase I clinical trial in patients with advanced cancer during the fourth quarter of 2009.
› Verified 3 days ago
| Provider Name | Vito Guario |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1366403446 PECOS PAC ID: 3274727243 Enrollment ID: I20101103000947 |
News Archive
Hospitals can dramatically reduce the number of life-threatening central line infections in pediatric cancer patients by following a set of basic precautions, by encouraging families to speak up when they observe noncompliance with the protocol and by honest analysis of the root cause behind every single infection, according to a new Johns Hopkins Children's Center study.
A new report published today, by the South Asian Health Foundation (SAHF) highlights that misunderstanding of diabetes in the South Asian community can be addressed by culturally appropriate education programmes.
With each new amyloid-targeting treatment for Alzheimer's disease that has been developed, there has been a corresponding concern. For example, antibodies targeting amyloid-β peptide (Aβ) produce inflammation in the brain in some patients.
An active lifestyle helps preserve gray matter in the brains of older adults and could reduce the burden of dementia and Alzheimer's disease (AD), according to a study presented today at the annual meeting of the Radiological Society of North America (RSNA).
Ascenta Therapeutics announced today that following the approval by the U.S. Food and Drug Administration (FDA) of its Investigational New Drug (IND) Application for AT-406, an orally-active, small molecule, multi-IAP antagonist, the company will initiate a Phase I clinical trial in patients with advanced cancer during the fourth quarter of 2009.
› Verified 3 days ago
| Provider Name | Alan B Aker |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1841269669 PECOS PAC ID: 4183634413 Enrollment ID: I20120627000109 |
News Archive
Hospitals can dramatically reduce the number of life-threatening central line infections in pediatric cancer patients by following a set of basic precautions, by encouraging families to speak up when they observe noncompliance with the protocol and by honest analysis of the root cause behind every single infection, according to a new Johns Hopkins Children's Center study.
A new report published today, by the South Asian Health Foundation (SAHF) highlights that misunderstanding of diabetes in the South Asian community can be addressed by culturally appropriate education programmes.
With each new amyloid-targeting treatment for Alzheimer's disease that has been developed, there has been a corresponding concern. For example, antibodies targeting amyloid-β peptide (Aβ) produce inflammation in the brain in some patients.
An active lifestyle helps preserve gray matter in the brains of older adults and could reduce the burden of dementia and Alzheimer's disease (AD), according to a study presented today at the annual meeting of the Radiological Society of North America (RSNA).
Ascenta Therapeutics announced today that following the approval by the U.S. Food and Drug Administration (FDA) of its Investigational New Drug (IND) Application for AT-406, an orally-active, small molecule, multi-IAP antagonist, the company will initiate a Phase I clinical trial in patients with advanced cancer during the fourth quarter of 2009.
› Verified 3 days ago
| Provider Name | Alexis Seidel |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1578187027 PECOS PAC ID: 3274998083 Enrollment ID: I20230501002188 |
News Archive
Hospitals can dramatically reduce the number of life-threatening central line infections in pediatric cancer patients by following a set of basic precautions, by encouraging families to speak up when they observe noncompliance with the protocol and by honest analysis of the root cause behind every single infection, according to a new Johns Hopkins Children's Center study.
A new report published today, by the South Asian Health Foundation (SAHF) highlights that misunderstanding of diabetes in the South Asian community can be addressed by culturally appropriate education programmes.
With each new amyloid-targeting treatment for Alzheimer's disease that has been developed, there has been a corresponding concern. For example, antibodies targeting amyloid-β peptide (Aβ) produce inflammation in the brain in some patients.
An active lifestyle helps preserve gray matter in the brains of older adults and could reduce the burden of dementia and Alzheimer's disease (AD), according to a study presented today at the annual meeting of the Radiological Society of North America (RSNA).
Ascenta Therapeutics announced today that following the approval by the U.S. Food and Drug Administration (FDA) of its Investigational New Drug (IND) Application for AT-406, an orally-active, small molecule, multi-IAP antagonist, the company will initiate a Phase I clinical trial in patients with advanced cancer during the fourth quarter of 2009.
› Verified 3 days ago
| Provider Name | Jonathan Edward Aker |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1093275927 PECOS PAC ID: 1759612450 Enrollment ID: I20230714003390 |
News Archive
Hospitals can dramatically reduce the number of life-threatening central line infections in pediatric cancer patients by following a set of basic precautions, by encouraging families to speak up when they observe noncompliance with the protocol and by honest analysis of the root cause behind every single infection, according to a new Johns Hopkins Children's Center study.
A new report published today, by the South Asian Health Foundation (SAHF) highlights that misunderstanding of diabetes in the South Asian community can be addressed by culturally appropriate education programmes.
With each new amyloid-targeting treatment for Alzheimer's disease that has been developed, there has been a corresponding concern. For example, antibodies targeting amyloid-β peptide (Aβ) produce inflammation in the brain in some patients.
An active lifestyle helps preserve gray matter in the brains of older adults and could reduce the burden of dementia and Alzheimer's disease (AD), according to a study presented today at the annual meeting of the Radiological Society of North America (RSNA).
Ascenta Therapeutics announced today that following the approval by the U.S. Food and Drug Administration (FDA) of its Investigational New Drug (IND) Application for AT-406, an orally-active, small molecule, multi-IAP antagonist, the company will initiate a Phase I clinical trial in patients with advanced cancer during the fourth quarter of 2009.
› Verified 3 days ago
News Archive
Hospitals can dramatically reduce the number of life-threatening central line infections in pediatric cancer patients by following a set of basic precautions, by encouraging families to speak up when they observe noncompliance with the protocol and by honest analysis of the root cause behind every single infection, according to a new Johns Hopkins Children's Center study.
A new report published today, by the South Asian Health Foundation (SAHF) highlights that misunderstanding of diabetes in the South Asian community can be addressed by culturally appropriate education programmes.
With each new amyloid-targeting treatment for Alzheimer's disease that has been developed, there has been a corresponding concern. For example, antibodies targeting amyloid-β peptide (Aβ) produce inflammation in the brain in some patients.
An active lifestyle helps preserve gray matter in the brains of older adults and could reduce the burden of dementia and Alzheimer's disease (AD), according to a study presented today at the annual meeting of the Radiological Society of North America (RSNA).
Ascenta Therapeutics announced today that following the approval by the U.S. Food and Drug Administration (FDA) of its Investigational New Drug (IND) Application for AT-406, an orally-active, small molecule, multi-IAP antagonist, the company will initiate a Phase I clinical trial in patients with advanced cancer during the fourth quarter of 2009.
› Verified 3 days ago
Boca Integrative Health Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 7100 W Camino Real, Ste. 207, Boca Raton, FL 33433 Phone: 561-391-2770 Fax: 561-391-2930 | |
Proactive Medical Solutions Pllc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 17808 Key Vista Way, Boca Raton, FL 33496 Phone: 646-456-4407 Fax: 888-254-2756 | |
Michelle Y Bruzzo Md Pa Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 1905 Clint Moore Rd, Suite 302, Boca Raton, FL 33496 Phone: 561-988-5387 Fax: 561-988-5388 | |
Gjorgji Trnovski Md Pa Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 1050 Nw 15th St, Suite 215a, Boca Raton, FL 33486 Phone: 561-955-1890 Fax: 561-392-8103 | |
Tamara Liss Md Pa Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 801 Meadows Rd, Suite 103, Boca Raton, FL 33486 Phone: 561-347-9044 Fax: 561-347-9043 | |
Daniel Ohara M D P A Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 660 Glades Rd, Suite # 380, Boca Raton, FL 33431 Phone: 561-393-1994 Fax: 561-393-2445 | |
Royal Family Medicine Inc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 3886 Candlewood Blvd, Boca Raton, FL 33487 Phone: 787-415-8405 |